<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02016781</url>
  </required_header>
  <id_info>
    <org_study_id>BMTCTN1102</org_study_id>
    <secondary_id>2U10HL069294-11</secondary_id>
    <secondary_id>5U24CA076518</secondary_id>
    <nct_id>NCT02016781</nct_id>
  </id_info>
  <brief_title>Allo vs Hypomethylating/Best Supportive Care in MDS (BMT CTN 1102)</brief_title>
  <official_title>A Multi-Center Biologic Assignment Trial Comparing Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients w/Intermediate-2 &amp; High Risk Myelodysplastic Syndrome (BMT CTN #1102)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Blood and Marrow Transplant Clinical Trials Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Marrow Donor Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed as a multicenter trial, with biological assignment to one of two study
      arms; Arm 1: Reduced intensity conditioning allogeneic hematopoietic cell transplantation
      (RIC-alloHCT), Arm 2: Non-Transplant Therapy/Best Supportive Care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: MDS is a clonal disorder of hematopoietic precursors and stem cells, which may
      evolve to a terminal phase resembling acute leukemia. A subject of clinical urgency for
      researchers, clinicians, patients, and health care underwriters such as Medicare, is the role
      of allogeneic hematopoietic cell transplantation (alloHCT) in the treatment of older patients
      with higher risk myelodysplastic syndromes (MDS). The use of reduced intensity conditioning
      (RIC) regimens has extended HCT to the care of older patients with acute myelogenous leukemia
      (AML) and lymphoma and a number of retrospective and phase II trials for patients with MDS
      now show the curative potential of RIC alloHCT in selected patients.

      This protocol is designed to evaluate the relative benefits of RIC alloHCT compared to
      non-transplant therapies focusing on overall survival. This will be done by having patients
      biologically assigned to the alloHCT arm or the hypomethylating therapy/best supportive care
      arm and following them for survival at 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2013</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival probabilities</measure>
    <time_frame>3 years</time_frame>
    <description>The primary objective for this study is to compare three-year overall survival probabilities between two treatment arms. Overall survival is calculated for all patients from date of patient consent until death from any cause. Observation is censored at the date of last follow-up for patients last known to be alive</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Leukemia-free survival (LFS)</measure>
    <time_frame>3 years</time_frame>
    <description>LFS is defined as the time from the date of patient consent to the date of progression to AML or death from any cause, whichever comes first. Observation is censored at the date of last follow-up for patients known to be alive without leukemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOL measures</measure>
    <time_frame>3 years</time_frame>
    <description>Health-Related QoL will be measured using patient reported surveys.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>MDS</condition>
  <arm_group>
    <arm_group_label>Transplant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Reduced intensity conditioning allogeneic hematopoietic cell transplantation (RIC-alloHCT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Transplant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hypomethylating Therapy / Best Supportive Care</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Cell Transplant</intervention_name>
    <description>Bone marrow or peripheral blood stem cell transplant.</description>
    <arm_group_label>Transplant</arm_group_label>
    <other_name>RIC alloHCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hypomethylating Therapy / Best Supportive Care</intervention_name>
    <description>The specific non-transplant treatment regimen will be at the discretion of the treating physician.</description>
    <arm_group_label>Non-Transplant</arm_group_label>
    <other_name>Non-transplant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reduced Intensity Conditioning</intervention_name>
    <description>The specific transplant treatment regimen will be at the discretion of the treating physician.</description>
    <arm_group_label>Transplant</arm_group_label>
    <other_name>RIC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients fulfilling the following criteria will be eligible for entry into this study:

               1. Patients with de novo MDS who have, or have previously had, Intermediate-2 or
                  High risk disease as determined by the International Prognostic Scoring System
                  (IPSS). Current Intermediate-2 or High risk disease is NOT a requirement.

               2. Patients must have an acceptable MDS subtype:

                    -  Refractory cytopenia with unilineage dysplasia (RCUD) (includes refractory
                       anemia (RA))

                    -  Refractory anemia with ringed sideroblasts (RARS)

                    -  Refractory anemia with excess blasts (RAEB-1)

                    -  Refractory anemia with excess blasts (RAEB-2)

                    -  Refractory cytopenia with multilineage dysplasia (RCMD)

                    -  Myelodysplastic syndrome with isolated del(5q) (5q-syndrome)

                    -  Myelodysplastic syndrome (MDS), unclassifiable

               3. Patients must have fewer than 20% marrow blasts within 60 days of consent.

               4. Patients may have received prior therapy for the treatment of MDS, including but
                  not limited to: growth factor, transfusion support, immunomodulatory (IMID)
                  therapy, DNA hypomethylating therapy, or cytotoxic chemotherapy prior to
                  enrollment.

               5. Age 50.0-75.0 years.

               6. Karnofsky performance status &gt; 70 or Eastern Cooperative Oncology Group (ECOG) â‰¤
                  1.

               7. Patients are eligible if no formal unrelated donor search has been activated
                  prior to date of consent. A formal unrelated donor search begins at the time at
                  which samples are requested from potential National Marrow Donor Program (NMDP)
                  donors. Patients who have started a sibling donor search or who have found a
                  matched sibling donor are eligible.

               8. Patients and physicians must be willing to comply with treatment assignment:

                    1. No intent to proceed with alloHCT using donor sources not specified in this
                       protocol, including human leukocyte antigen (HLA)-mismatched related or
                       unrelated donors (&lt; 6/6 HLA related matched or &lt; 8/8 HLA unrelated matched)
                       or umbilical cord blood unit(s).

                    2. No intent to use myeloablative conditioning regimens.

                    3. Intent to proceed with RIC alloHCT if a matched sibling or matched unrelated
                       donor is identified. There is no requirement as to the timing of the
                       transplantation.

               9. Patients must be considered to be suitable RIC alloHCT candidates at the time of
                  enrollment based on medical history, physical examination, and available
                  laboratory tests. Specific testing for organ function is not required for
                  eligibility but, if available, these tests should be used to judge eligibility.

              10. Signed informed consent

        Exclusion Criteria:

          -  Patients with the following will be ineligible for registration onto this study:

               1. Therapy-related MDS (defined as the occurrence of MDS due to prior exposure to
                  systemic chemotherapy and/or radiation for malignancy)

               2. Current or prior diagnosis of AML

               3. Chronic myelomonocytic leukemia or myelodysplastic/myeloproliferative neoplasm
                  (unacceptable MDS subtypes); uncontrolled bacterial, viral or fungal infection
                  (currently taking medication and with progression or no clinical improvement) at
                  time of enrollment.

               4. Patients with prior malignancies, except treated non-melanoma skin cancer or
                  treated cervical carcinoma in situ. Cancer treated with curative surgery without
                  chemotherapy/radiation therapy &gt; 5 years previously will be allowed. Cancer
                  treated with curative surgery &lt; 5 years previously will not be allowed unless
                  approved by the Protocol Officer or one of the Protocol Chairs.

               5. Prior autologous or allogeneic HCT

               6. Human Immunodeficiency Virus (HIV) infection

               7. Patients of childbearing potential unwilling to use contraceptive techniques

               8. Patients with psychosocial conditions that would prevent study compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Horowitz, MD, MS</last_name>
    <role>Study Director</role>
    <affiliation>Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alyssa Ramirez</last_name>
    <email>aramirez@emmes.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adam Mendizabal, PhD</last_name>
    <email>amendizabal@emmes.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryotaro Nakamura, MD</last_name>
      <phone>626-256-4673</phone>
      <email>RNakamura@coh.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford Hospital and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Benjamin, MD</last_name>
      <phone>650-723-0822</phone>
      <email>jbenjam@Stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Florida College of Medicine</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-0277</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Wingard, MD</last_name>
      <email>john.wingard@medicine.ufl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33624</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martha Arellano, MD</last_name>
      <email>marella@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Artz, MD, MS</last_name>
      <phone>773-834-8980</phone>
      <email>aartz@medicine.bsd.uchicago.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph McGuirk, DO</last_name>
      <phone>913-588-9031</phone>
      <email>jmcguirk@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roger Herzig, MD</last_name>
      <email>roger.herzig@uky.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Systems - Greenebaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aaron Rapoport, MD</last_name>
      <email>arapoport@umm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Showel, MD</last_name>
      <email>mshowel1@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute/Brigham &amp; Women's</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corey Cutler, MD, MPH</last_name>
      <phone>617-632-5946</phone>
      <email>corey_cutler@dfci.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute/Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi-Bin Chen, MD</last_name>
      <email>Ychen6@partners.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute/BMT</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Voravit Ratanatharathorn, MD</last_name>
      <email>ratanath@karmanos.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mrinal Patnaik, MD</last_name>
      <email>patnaik.mrinal@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University/Barnes Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Westervelt, MD, PhD</last_name>
      <phone>314-454-8306</phone>
      <email>pwestervelt9876@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Maness-Harris, MD</last_name>
      <email>lmaness@unmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip McCarthy, MD</last_name>
      <email>philip.mccarthy@roswellpark.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roni Tamari</last_name>
      <email>Tamarir@mskcc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Hospital at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomas Shea, MD</last_name>
      <email>tom_shea@med.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Shea, MD</last_name>
      <phone>919-966-7746</phone>
      <email>tom_shea@med.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitchell Horwitz, MD</last_name>
      <email>mitchell.horwitz@duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Hurd, MD</last_name>
      <email>dhurd@wfubmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jewish Hospital BMT Program</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland/ Case Western</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hillard Lazarus, MD</last_name>
      <email>hillard.lazarus@case.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aaron Gerds, MD</last_name>
      <email>gerdsa@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State/Arthur G. James Cancer Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Devine, MD</last_name>
      <email>steven.devine@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Maziarz</last_name>
      <email>maziarzr@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Mangan, MD</last_name>
      <email>james.mangan@uphs.upenn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-8210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine/The Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rammurti Kamble</last_name>
      <email>Kamble@bcm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas/MD Anderson CRC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Betul Oran, MD</last_name>
      <email>boran@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Utah Med School</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tibor Kovacsovics, MD</last_name>
      <email>tibor.kovacsovics@hci.utah.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University MCV Hospitals</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John McCarty, MD</last_name>
      <phone>804-828-4596</phone>
      <email>jmccarty@vcu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bart Scott, MD</last_name>
      <email>bscott@fhcrc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Virginia University Hospital</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Craig, MD</last_name>
      <email>craigm@wvuhealthcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wael Saber, MD</last_name>
      <email>wsaber@mcw.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bmtctn.net/</url>
    <description>Blood and Marrow Transplant Clinical Trials Network Website</description>
  </link>
  <link>
    <url>http://bethematch.org</url>
    <description>National Marrow Donor Program</description>
  </link>
  <reference>
    <citation>Saber W, Le Rademacher J, Sekeres M, Logan B, Lewis M, Mendizabal A, Leifer E, Appelbaum FR, Horowitz MM, Nakamura R, Cutler CS. Multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome: Blood and Marrow Transplant Clinical Trials Network #1102 study rationale, design, and methods. Biol Blood Marrow Transplant. 2014 Oct;20(10):1566-72. doi: 10.1016/j.bbmt.2014.06.010. Epub 2014 Jun 24.</citation>
    <PMID>24972249</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2013</study_first_submitted>
  <study_first_submitted_qc>December 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2013</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myelodysplastic Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Results will be published in a manuscript and supporting information submitted to NIH BioLINCC (including data dictionaries, case report forms, data submission documentation, documentation for outcomes dataset, etc where indicated).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

